Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2010, Article ID 351045, 4 pages
http://dx.doi.org/10.1155/2010/351045
Clinical Study

Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

1Berrenratherstr. 296, 50937 Köln, Germany
2Durenerstr. 332, 50935 Köln, Germany
3Institute of Medical Statistics and Epidemiology, University of Cologne, 50924 Köln, Germany

Received 4 April 2010; Revised 1 September 2010; Accepted 20 October 2010

Academic Editor: Bruno Brochet

Copyright © 2010 Damian Franzen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Franzen, A. Haus, and M. Hellmich, “Continuous reduction of left ventricular pump function during mitoxantrone—therapy in multiple sclerosis,” Aktuelle Neurologie, vol. 33, no. 6, pp. 322–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Franzen, C. Apel, A. Haus, and H. Hellmich, “Persistent left ventricular dysfunction following cessation of mitoxantrone—therapy in patients with multiple sclerosis,” Aktuelle Neurologie, vol. 35, no. 9, pp. 430–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. E. Gonsette, “A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 4, pp. 747–765, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. E. C. Van Dalen, H. J. H. Van Der Pal, P. J. M. Bakker, H. N. Caron, and L. C. M. Kremer, “Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review,” European Journal of Cancer, vol. 40, no. 5, pp. 643–652, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. P. Hartung, R. Gonsette, N. König et al., “Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial,” Lancet, vol. 360, no. 9350, pp. 2018–2025, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Spindler, F. Weilbach, M. Beer et al., “Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis,” Journal of Cardiovascular Pharmacology, vol. 42, no. 5, pp. 680–687, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Avasarala, A. H. Cross, D. B. Clifford, B. A. Singer, B. A. Siegel, and E. E. Abbey, “Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis,” Multiple Sclerosis, vol. 9, no. 1, pp. 59–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Pattoneri, F. Sozzi, G. Pela et al., “Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue doppler echocardiographic analysis,” Echocardiography, vol. 26, no. 4, pp. 397–402, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. De Castro, D. Cartoni, E. Millefiorini et al., “Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis,” Journal of Clinical Pharmacology, vol. 35, no. 6, pp. 627–632, 1995. View at Google Scholar · View at Scopus
  10. V. C. Zingler, M. Näbauer, K. Jahn et al., “Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis,” European Neurology, vol. 54, no. 1, pp. 28–33, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Bertora, D. Torzillo, G. Baldi, T. Vago, and C. Mariani, “Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone,” Journal of Neurology, vol. 255, no. 1, pp. 140–141, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. D. Cheitlin, J. S. Alpert, W. F. Armstrong et al., “ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association task force on practice guidelines,” Circulation, vol. 95, no. 6, pp. 1686–1744, 1997. View at Google Scholar · View at Scopus
  13. E. Bernitsas, W. Wei, and D. D. Mikol, “Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane,” Annals of Neurology, vol. 59, no. 1, pp. 206–209, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus